To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Trimeris' HIV Fusion Inhibitor Receives Fast Track Designation From FDA URL: http://www.pslgroup.com/dg/FEB0E.htm Doctor's Guide May 19, 1999
DURHAM, NC -- May 19, 1999 -- Trimeris, Inc.'s T-1249 has received fast track designation from the United States Food and Drug Administration for the treatment of HIV infected individuals. T-1249 is the company's second drug candidate in a new class of anti-HIV compounds that block the entry of the virus into cells. Fast track designation is granted to products that may provide a significant improvement in the safety or effectiveness of the treatment for a serious or life-threatening disease and this designation is intended to expedite the FDA's review of these drugs. T-1249 is a rationally designed proprietary peptide which blocks fusion of HIV with host cells. T-1249 has demonstrated potent HIV suppression in animal models and is highly active against a wide range of HIV strains in culture. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.